Impact Partnership Wealth LLC Has $433,000 Stock Position in Illumina, Inc. $ILMN

Impact Partnership Wealth LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 57.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,300 shares of the life sciences company’s stock after selling 4,529 shares during the period. Impact Partnership Wealth LLC’s holdings in Illumina were worth $433,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. Empowered Funds LLC lifted its position in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after acquiring an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in Illumina in the 2nd quarter valued at $621,000. CW Advisors LLC bought a new stake in Illumina in the 2nd quarter valued at $275,000. Marshall Wace LLP lifted its position in Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC lifted its position in Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 2.7%

Shares of NASDAQ:ILMN opened at $162.96 on Friday. The company’s 50-day moving average price is $133.73 and its two-hundred day moving average price is $132.02. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a one year low of $78.79 and a one year high of $165.37. The stock has a market capitalization of $24.66 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 2.70 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the firm posted $0.97 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of several research reports. Barclays boosted their price objective on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Canaccord Genuity Group cut their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Citigroup boosted their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $137.75.

Insider Activity

In other Illumina news, Director Keith A. Meister sold 104,393 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the sale, the director directly owned 3,500,048 shares of the company’s stock, valued at $508,696,976.32. The trade was a 2.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 330,160 shares of company stock worth $48,028,308 over the last three months. Insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.